AndroGel and Rosuvastatin Interaction: Safety, Monitoring, and Dose Guidance

AndroGel is a brand of transdermal testosterone gel (available in 1% and 1.62% strengths), FDA-approved for testosterone replacement in men with confirmed hypogonadism. Rosuvastatin (brand name Crestor) is an HMG-CoA reductase inhibitor (statin) FDA-approved for lowering LDL cholesterol and reducing cardiovascular risk. This page addresses whether the two can be used together and what actually needs to be watched.

The core, quotable answer: AndroGel and rosuvastatin do not have a known drug-drug pharmacokinetic interaction, based on rosuvastatin's FDA-approved label describing its transporter-dependent, largely non-CYP clearance pathway. What clinicians actually need to manage is a pharmacodynamic effect, testosterone's tendency to alter lipid values, which is monitored with a fasting lipid panel rather than avoided by withholding either drug. Whether this lipid shift is large enough to require a statin dose change is decided by the individual's lipid response, not by a fixed rule that applies to everyone on this combination.

What is established, what is plausible, and what is not established

Established (FDA label / regulatory basis):

• Rosuvastatin's prescribing information describes clearance driven mainly by hepatic uptake transporters (OATP1B1/OATP1B3) and biliary excretion, with only a minor CYP2C9 contribution, a pathway that testosterone is not documented to inhibit. (Crestor label, accessdata.fda.gov)
• The AndroGel label carries warnings about increased hematocrit/polycythemia risk and a boxed warning on secondary testosterone exposure through skin contact; it does not list rosuvastatin as a labeled interaction. (per the AndroGel prescribing information)
• The FDA has issued safety communications about statin-class hepatic and muscle effects generally, applicable across statins including rosuvastatin. (per general FDA safety communications about statin-class hepatic and muscle effects)

Plausible but not precisely quantified here:

• Published research on testosterone replacement therapy has reported changes in lipid profile, including possible increases in LDL-C and decreases in HDL-C in some men, with effect size varying by study, dose, formulation, and baseline metabolic status. The exact magnitude figures that circulate in secondary sources for this combination have not been independently verified against the primary papers for this draft and should be confirmed before being presented as precise numbers in a clinical resource.
• Independent research (the TTrials Cardiovascular sub-study) reported a signal of increased coronary artery plaque volume with testosterone gel in men over 65; whether this changes the risk-benefit calculation for a man already on a statin for cardiovascular protection is not settled and needs case-by-case cardiology input rather than a blanket rule.

Not established:

• There is no established evidence that testosterone gel meaningfully alters rosuvastatin blood levels or efficacy through a pharmacokinetic mechanism.
• There is no established rule for exactly how much to increase a statin dose in response to testosterone-associated lipid changes; this is individualized, guided by lipid response and the patient's overall ASCVD risk category, not a fixed protocol.

Why the CYP/transporter pathway is not the concern here

Rosuvastatin is unusual among statins in that it depends heavily on hepatic uptake transporters rather than CYP3A4 metabolism, which is why the FDA label lists cyclosporine and certain protease inhibitors, known OATP inhibitors, as the drugs that matter for rosuvastatin plasma levels, not androgens. Simvastatin and lovastatin, by contrast, rely on CYP3A4 and carry FDA labeling around CYP3A4 inhibitors. That distinction is worth knowing if a patient or prescriber is comparing which statin "interacts less" with testosterone therapy, but it does not by itself make rosuvastatin risk-free with androgens, it simply removes one specific mechanism from consideration.

The real issue: testosterone's effect on the lipid panel

The reason this combination gets flagged in interaction checkers is pharmacodynamic, not enzymatic. Testosterone replacement has been studied for its effects on lipid metabolism, and multiple trials and reviews have suggested a tendency toward higher LDL-C and lower HDL-C in some men on therapy, particularly during the first year. The direction of the effect appears reasonably consistent across the literature; the exact size of the effect varies enough between studies and formulations that a single precise percentage should not be treated as authoritative without checking the specific trial population and testosterone formulation involved.

Practically, this means a man whose LDL-C is well controlled on rosuvastatin before starting AndroGel may see that control loosen after starting testosterone therapy. It does not mean the statin has stopped working or that the two drugs cannot be used together, it means the lipid panel needs to be rechecked after starting or adjusting testosterone, and the statin regimen re-evaluated based on that result, in consultation with the prescriber.

Liver enzyme monitoring: shared but not identical risk

Both drug classes carry some hepatic monitoring relevance. Transdermal testosterone gel bypasses first-pass liver metabolism and carries substantially lower hepatotoxicity risk than oral androgens, per the AndroGel label. Rosuvastatin, like other statins, lists transaminase elevation as a possible adverse reaction in its label, generally uncommon at approved doses. A single hepatic panel can reasonably cover monitoring needs for both drugs rather than requiring separate testing schedules, but the decision about testing frequency belongs to the prescribing clinician based on baseline liver status and dose.

Hematocrit: a testosterone-specific monitoring layer

Testosterone stimulates red blood cell production, and elevated hematocrit (erythrocytosis/polycythemia) is a recognized risk on testosterone therapy per the AndroGel label. Rosuvastatin has no known effect on red cell mass, so hematocrit monitoring on this combination is driven entirely by the testosterone component. This matters for the interaction discussion because a man on rosuvastatin for cardiovascular risk reduction who develops testosterone-associated erythrocytosis is adding an independent cardiovascular risk factor that the statin does not address, a reason for coordinated monitoring even though it is not a classic drug-drug interaction.

Muscle symptoms and CK: a diagnostic overlap, not a drug interaction

Statin-associated muscle symptoms are a recognized issue across the statin class, and rosuvastatin is generally reported to have a lower incidence than some other statins at equivalent LDL-lowering doses, though the risk is not zero. Testosterone therapy can independently raise creatine kinase through increased muscle mass and exercise intensity, particularly in men who become more active once symptoms of hypogonadism improve. In practice, new myalgia in a man on both drugs is a diagnostic question, is this statin myopathy, exercise-related CK elevation, or both, that a baseline CK before starting therapy helps answer, rather than something that can be resolved by a fixed cutoff alone.

Evidence-status assessment: AndroGel + rosuvastatin

What this means for dose decisions

No dose reduction of either drug is automatically required when the two are combined. The more common clinical response, if it happens, is an adjustment to the statin regimen based on a follow-up lipid panel, not a change to the testosterone dose, since AndroGel dosing is guided by testosterone trough levels and symptom response, not by lipid numbers. Whether and how much to adjust rosuvastatin, or whether to add a non-statin lipid-lowering therapy, is a decision for the prescribing clinician based on the individual's lipid trend and cardiovascular risk category. This page cannot and should not substitute for that individualized assessment.

When to involve a specialist or seek prompt evaluation

Consider escalation to an endocrinologist, cardiologist, or the prescribing physician promptly if:

• LDL-C rises substantially after starting testosterone therapy and remains above the patient's individualized target despite statin therapy.
• Hematocrit is elevated on repeat testing while on testosterone therapy.
• The patient has established atherosclerotic cardiovascular disease (prior heart attack, stent, or stroke) and is considering starting testosterone therapy for the first time.
• New or worsening muscle pain occurs on the combination, this should be evaluated rather than assumed to be either drug alone.
• Transaminases rise significantly above baseline and the cause is unclear.

Severe muscle pain with weakness, dark urine, or signs of liver injury (jaundice, severe abdominal pain, unusual fatigue) warrants urgent medical evaluation rather than waiting for a routine follow-up.

Formulation and counseling notes specific to AndroGel

AndroGel's two concentrations (1% and 1.62%) differ in delivery amount per application but do not differ in their pharmacodynamic lipid effect, since that effect depends on systemic testosterone exposure rather than the gel vehicle. Separately from the rosuvastatin question, AndroGel carries a boxed warning about secondary exposure: testosterone gel can transfer via skin contact to women and children and cause virilization. Patients should apply the gel to the shoulders or upper arms, let it dry fully, and keep the area covered until contact with others is safe. This has no bearing on the rosuvastatin interaction but is a required part of counseling whenever AndroGel is prescribed.